An open-label, Phase 1b study of TG02 in combination with Carfilzomib assessing safety and efficacy in Carfilzomib Refractory Multiple Myeloma Patients.

Trial Profile

An open-label, Phase 1b study of TG02 in combination with Carfilzomib assessing safety and efficacy in Carfilzomib Refractory Multiple Myeloma Patients.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Jan 2016

At a glance

  • Drugs TG 02 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 Jan 2016 New trial record
    • 08 Dec 2015 Interim results (n=24) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top